Literature DB >> 15958363

Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy.

M Vanderheyden1, W J Paulus, M Voss, P Knuefermann, N Sivasubramanian, D Mann, G Baumgarten.   

Abstract

OBJECTIVE: To investigate cytokine gene expression in patients with aortic valve stenosis (AS) and with idiopathic dilated cardiomyopathy (DCM), and to correlate wall stress with myocardial proinflammatory cytokine gene expression.
METHODS: Human left ventricular (LV) myocardial biopsies were obtained for subsequent reverse transcription polymerase chain reaction of tumour necrosis factor alpha (TNFalpha), interleukin (IL)-1beta, and IL-6 mRNA. The study population consisted of 24 patients with AS and 10 patients with idiopathic DCM.
RESULTS: Patients with AS had a larger ejection fraction (56 (5) v 37 (4)%, p < 0.01), smaller LV end diastolic volumes (146 (11) v 267 (21) ml, p < 0.01), and lower end systolic wall stress (44 (7) v 112 (11) kdyn/cm2, p < 0.001). Upregulation of TNFalpha, IL-1beta, and IL-6 gene expression was detected in both groups. However, TNFalpha gene expression was significantly higher in AS than in DCM (p = 0.009). No correlation was found between haemodynamic parameters and TNFalpha gene expression. In patients with AS there was a strong inverse relation between circulating TNFalpha and TNFalpha gene expression (r = -0.685, p = 0.014), between circulating TNFalpha and IL-1beta gene expression (r = -0.664, p = 0.018), and between soluble TNF receptor 2 and TNFalpha gene expression (r = -0.685, p = 0.020). Myocardial gene expression of TNFalpha was significantly higher in patients with well compensated AS than in patients with decompensated AS (p = 0.017). Similarly, patients with decompensated DCM were characterised by significantly lower TNFalpha gene expression than were patients with well compensated DCM (p = 0.011).
CONCLUSION: TNFalpha gene expression is significantly higher in patients with pressure overload than in normal hearts, in patients with idiopathic DCM, and in patients with compensated versus decompensated heart failure. Secondly, in patients with AS proinflammatory cytokine gene expression did not affect systolic performance. The higher TNFalpha gene expression in patients with compensated heart failure suggests that cytokine gene expression has an adaptive role in the early phase of LV remodelling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958363      PMCID: PMC1768970          DOI: 10.1136/hrt.2004.035733

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  36 in total

1.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

2.  Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart.

Authors:  F Wang; Y Seta; G Baumgarten; D J Engel; N Sivasubramanian; D L Mann
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

3.  Cytokine-mediated apoptosis in cardiac myocytes: the role of inducible nitric oxide synthase induction and peroxynitrite generation.

Authors:  M A Arstall; D B Sawyer; R Fukazawa; R A Kelly
Journal:  Circ Res       Date:  1999-10-29       Impact factor: 17.367

4.  Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy.

Authors:  S F Nagueh; S J Stetson; N M Lakkis; D Killip; A Perez-Verdia; M L Entman; W H Spencer; G Torre-Amione
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

5.  Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices.

Authors:  E J Birks; N Latif; V Owen; C Bowles; L E Felkin; A J Mullen; A Khaghani; P J Barton; J M Polak; J R Pepper; N R Banner; M H Yacoub
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

6.  Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload.

Authors:  S R Kapadia; K Yakoob; S Nader; J D Thomas; D L Mann; B P Griffin
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

7.  Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.

Authors:  N Sivasubramanian; M L Coker; K M Kurrelmeyer; W R MacLellan; F J DeMayo; F G Spinale; D L Mann
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

8.  Activation of the cardiac interleukin-6 system in advanced heart failure.

Authors:  G Plenz; Z F Song; T D Tjan; C Koenig; H A Baba; M Erren; M Flesch; T Wichter; H H Scheld; M C Deng
Journal:  Eur J Heart Fail       Date:  2001-08       Impact factor: 15.534

9.  Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts.

Authors:  E J Birks; P B Burton; V Owen; A J Mullen; D Hunt; N R Banner; P J Barton; M H Yacoub
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

10.  Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery.

Authors:  G Torre-Amione; S J Stetson; K A Youker; J B Durand; B Radovancevic; R M Delgado; O H Frazier; M L Entman; G P Noon
Journal:  Circulation       Date:  1999-09-14       Impact factor: 29.690

View more
  20 in total

Review 1.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Authors:  Gabriele G Schiattarella; Joseph A Hill
Journal:  Circulation       Date:  2015-04-21       Impact factor: 29.690

Review 2.  Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.

Authors:  N Glezeva; J A Baugh
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

3.  Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A.

Authors:  Elangovan Vellaichamy; Kiran Kaur; Kailash N Pandey
Journal:  Peptides       Date:  2006-12-20       Impact factor: 3.750

4.  Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy.

Authors:  Jie Huang; Yang Liu; Jia-Xin Chen; Xin-Ya Lu; Wen-Jia Zhu; Le Qin; Zi-Xuan Xun; Qiu-Yi Zheng; Er-Min Li; Ning Sun; Chen Xu; Hai-Yan Chen
Journal:  Acta Pharmacol Sin       Date:  2021-03-30       Impact factor: 7.169

5.  Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice.

Authors:  Umadevi Subramanian; Prerna Kumar; Indra Mani; David Chen; Isaac Kessler; Ramu Periyasamy; Giri Raghavaraju; Kailash N Pandey
Journal:  Physiol Genomics       Date:  2016-05-06       Impact factor: 3.107

6.  Genetically altered mutant mouse models of guanylyl cyclase/natriuretic peptide receptor-A exhibit the cardiac expression of proinflammatory mediators in a gene-dose-dependent manner.

Authors:  Elangovan Vellaichamy; Subhankar Das; Umadevi Subramanian; Nobuyo Maeda; Kailash N Pandey
Journal:  Endocrinology       Date:  2014-01-01       Impact factor: 4.736

Review 7.  Regulation of cardiac angiotensin-converting enzyme and angiotensin AT1 receptor gene expression in Npr1 gene-disrupted mice.

Authors:  Kailash N Pandey; Elangovan Vellaichamy
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-10-16       Impact factor: 2.557

Review 8.  The role of IL-1 in the pathogenesis of heart disease.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

Review 9.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

Authors:  Stephane Heymans; Emilio Hirsch; Stefan D Anker; Pal Aukrust; Jean-Luc Balligand; Jan W Cohen-Tervaert; Helmut Drexler; Gerasimos Filippatos; Stephan B Felix; Lars Gullestad; Denise Hilfiker-Kleiner; Stefan Janssens; Roberto Latini; Gitte Neubauer; Walter J Paulus; Burkert Pieske; Piotr Ponikowski; Blanche Schroen; Heinz-Peter Schultheiss; Carsten Tschöpe; Marc Van Bilsen; Faiez Zannad; John McMurray; Ajay M Shah
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

Review 10.  How can we cure a heart "in flame"? A translational view on inflammation in heart failure.

Authors:  Ulrich Hofmann; Stefan Frantz
Journal:  Basic Res Cardiol       Date:  2013-06-06       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.